| dc.contributor | Universidade Estadual Paulista (Unesp) | |
| dc.date.accessioned | 2014-05-20T13:24:27Z | |
| dc.date.available | 2014-05-20T13:24:27Z | |
| dc.date.created | 2014-05-20T13:24:27Z | |
| dc.date.issued | 2005-02-16 | |
| dc.identifier | International Journal of Pharmaceutics. Amsterdam: Elsevier B.V., v. 290, n. 1-2, p. 137-144, 2005. | |
| dc.identifier | 0378-5173 | |
| dc.identifier | http://hdl.handle.net/11449/7591 | |
| dc.identifier | 10.1016/j.ijpharm.2004.11.027 | |
| dc.identifier | WOS:000226985500015 | |
| dc.description.abstract | Praziquantel has been shown to be highly effective against all known species of Schistosoma infecting humans. Spherical nanoparticulate drug carriers made of poly(D,L-lactide-co-glycolide) acid with controlled size were designed. Praziquantel, a hydrophobic molecule, was entrapped into the nanoparticles with theoretical loading varying from 10 to 30% (w/w). This investigates the effects of some process variables on the size distribution of nanoparticles prepared by emulsion-solvent evaporation method. The results show that sonication time, PLGA and drug amounts, PVA concentration, ratio between aqueous and organic phases, and the method of solvent evaporation have a significant influence on size distribution of the nanoparticles. (C) 2004 Elsevier B.V. All rights reserved. | |
| dc.language | eng | |
| dc.publisher | Elsevier B.V. | |
| dc.relation | International Journal of Pharmaceutics | |
| dc.relation | 3.862 | |
| dc.relation | 1,172 | |
| dc.rights | Acesso restrito | |
| dc.source | Web of Science | |
| dc.subject | nanoparticles | |
| dc.subject | controlled release | |
| dc.subject | PLGA | |
| dc.subject | praziquantel | |
| dc.subject | emulsification evaporation method | |
| dc.title | PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution | |
| dc.type | Artículos de revistas | |
